605
Participants
Start Date
November 29, 2016
Primary Completion Date
March 25, 2020
Study Completion Date
April 28, 2023
Nivolumab
Ipilimumab
Pemetrexed
Cisplatin
Carboplatin
Local Institution - 0124, Kunming
Local Institution - 0039, Bogotá
Local Institution - 0040, Bogotá
Local Institution - 0036, Lausanne
Local Institution - 0089, Brussels
Local Institution - 0032, Sydney
Local Institution - 0086, Edegem
Local Institution - 0049, Bern
Local Institution - 0030, Malvern
Local Institution - 0033, Clayton
Local Institution - 0087, Liège
Local Institution - 0031, Birtinya
Local Institution - 0034, Nedlands
Local Institution - 0059, Cape Town
Local Institution - 0029, Zurich
Local Institution - 0088, Sint-Niklaas
Memorial Sloan Kettering Nassau, New York
Local Institution - 0017, Athens
Local Institution - 0069, Marseille
Local Institution - 0053, Mexico City
Local Institution - 0057, Caen
Local Institution - 0050, Mexico City
Allegheny Cancer Center, Pittsburgh
Local Institution - 0045, Genova
University Of Pennsylvania, Philadelphia
Local Institution - 0048, Rozzano
Local Institution - 0027, Hamburg
Univ Of Maryland Greenbaum Cancer Center, Baltimore
Local Institution - 0111, Diyarbakır
Local Institution - 0024, Großhansdorf
West Virginia University, Morgantown
Local Institution - 0118, Chihuahua City
Local Institution - 0068, Toulouse
Local Institution - 0047, Aviano
H. Lee Moffitt Cancer Center & Research Inst, Inc, Tampa
Local Institution - 0112, Istanbul
Local Institution - 0022, Immenhausen
Local Institution - 0023, Göttingen
Local Institution - 0074, La Tronche
Local Institution - 0007, Cleveland
Local Institution - 0051, Guadalajara
Local Institution - 0080, Saint-Herblain
Local Institution - 0038, Essen
Local Institution - 0019, Moers
Local Institution - 0042, Ravenna
Local Institution - 0013, Detroit
Cancer & Hematology Centers Of Western Michigan, Grand Rapids
Local Institution - 0026, Cologne
Local Institution - 0041, Siena
Local Institution - 0004, Rochester
Local Institution - 0016, Thessaloniki
Local Institution - 0067, Lille
Local Institution - 0002, Chicago
Local Institution - 0021, Homburg An D. Saar
Local Institution - 0093, Strasbourg
Local Institution - 0037, Heidelberg
Local Institution - 0044, Bari
Local Institution - 0056, Paris
Local Institution - 0005, Houston
Local Institution - 0043, Napoli
Local Institution - 0058, Toulon
Local Institution - 0073, Créteil
Ucsf, San Francisco
Local Institution - 0046, Catania
Local Institution - 0150, Moscow
Local Institution - 0071, Moscow
Local Institution, Changchun
Local Institution - 0133, Harbin
Local Institution - 0072, Saint Petersburg
Local Institution - 0120, Shanghai
Local Institution - 0102, Craiova
Local Institution - 0055, Romania
Local Institution - 0094, Chuo-ku
Local Institution - 0095, Yokohama
Local Institution - 0097, Chiba
Local Institution - 0096, Kitaadachi-gun
Local Institution - 0105, Nagoya
Local Institution - 0113, Sayama
Local Institution - 0106, Amagasaki-shi
Local Institution - 0098, Nishinomiya-shi
Local Institution - 0100, Okayama
Local Institution - 0108, Fukuyama-shi
Local Institution - 0114, Hiroshima
Local Institution - 0099, Ube-shi
Local Institution - 0018, Santiago
Local Institution - 0107, Niigata
Local Institution - 0104, Natori-shi
Local Institution - 0014, New Haven
Local Institution, Barretos
Local Institution - 0064, São Paulo
Local Institution, Shenyang
Local Institution - 0054, Coswig
Local Institution - 0101, Sapporo
Local Institution - 0079, Df
Local Institution - 0092, Amsterdam
Local Institution - 0091, Rotterdam
Local Institution - 0078, Bytom
Local Institution - 0076, Krakow
Local Institution - 0077, Warsaw
Local Institution - 0115, Bucharest
Local Institution - 0109, Bucharest
Local Institution - 0060, Pretoria
Local Institution - 0110, Seyhan
Local Institution - 0085, Truro
Local Institution - 0084, Edinburgh
Local Institution - 0081, Leicester
Local Institution - 0083, London
Local Institution - 0116, Manchester
Local Institution - 0090, Southampton
Lead Sponsor
Collaborators (1)
Ono Pharmaceutical Co. Ltd
INDUSTRY
Bristol-Myers Squibb
INDUSTRY